Hikma Pharmaceuticals (LON:HIK) Receives “Buy” Rating from Deutsche Bank Aktiengesellschaft

Posted by Lauren Steadman on Jun 22nd, 2026

Hikma Pharmaceuticals (LON:HIK – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Deutsche Bank Aktiengesellschaft in a report released on Monday,Digital Look reports. They currently have a GBX 195 price target on the stock. Deutsche Bank Aktiengesellschaft’s target price would suggest a potential downside of 86.80% from the company’s current price.

Several other equities analysts also recently weighed in on HIK. Berenberg Bank reissued a “buy” rating and issued a GBX 1,800 price target on shares of Hikma Pharmaceuticals in a research note on Tuesday, April 28th. Jefferies Financial Group increased their price objective on shares of Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a report on Tuesday, May 5th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Hikma Pharmaceuticals has an average rating of “Buy” and an average price target of GBX 1,687.

View Our Latest Research Report on Hikma Pharmaceuticals

Hikma Pharmaceuticals Trading Up 1.4%

Shares of HIK opened at GBX 1,477 on Monday. Hikma Pharmaceuticals has a 52-week low of GBX 1,187 and a 52-week high of GBX 2,074. The stock has a market cap of £3.14 billion, a PE ratio of 8.16, a price-to-earnings-growth ratio of 2.38 and a beta of 0.65. The firm’s fifty day moving average is GBX 1,422.57 and its two-hundred day moving average is GBX 1,447.22. The company has a quick ratio of 1.27, a current ratio of 1.82 and a debt-to-equity ratio of 61.84.

Hikma Pharmaceuticals Company Profile

(Get Free Report)

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.